How AI-Enabled Real-World Evidence Solutions are Impacting Pharma’s Value Chain

AI is transforming how Real-World Evidence (RWE) solution providers change the way Pharma’s decision making along the value chain. By automating data harmonization and deriving insights from diverse Real-World Data (RWD) sources — including electronic health records, genomics, and wearable devices — AI enables RWE to function as a scalable decision-support engine across research, development, and commercialization. The six leading solution categories are currently the most advanced in integrating AI capabilities.

For over a decade, RWE was positioned as a bridge between controlled clinical studies and real-world outcomes. The potential was clear: faster studies, more representative populations, and stronger post-market evidence. The challenge lay in fragmented data, inconsistent quality, and manual analytical workflows.

Today, AI is closing that gap. With advances in multimodal learning, NLP, and generative models, RWE has evolved from a retrospective research tool into a strategic capability integrated throughout drug development, approval, and commercialization.

I. Discovery & Research: From Data Noise to Targeted Discovery

AI-driven RWE platforms are accelerating early discovery by integrating clinical, genomic, and phenotypic datasets to uncover disease mechanisms and biomarkers.
Deep learning and predictive analytics enable scientists to model disease progression and stratify patients based on real-world characteristics.

Representative Solutions: Owkin, Aitia, BenevolentAI, Valo Health, Healx, Insilico Medicine

Strategic Impact: Reduces preclinical attrition, supports precision drug design, and builds translational bridges between lab findings and patient outcomes.

II. Clinical Development: Building Trials on Real-World Foundations

AI enhances clinical trial design and operations by using RWE to simulate control arms, optimize site selection, and accelerate patient recruitment.
Machine learning models identify eligible and diverse participants, while NLP enables automated EHR parsing and patient-matching across large datasets.

Representative Solutions: Unlearn.AI, Verana Health, ConcertAI, CureMetrix, Saama Technologies, TriNetX

Strategic Impact: Reduces trial duration and cost, enhances diversity and regulatory credibility, and enables adaptive evidence generation.

III. Regulatory Evidence: Faster, Transparent, and Traceable Submissions

Generative AI and advanced analytics platforms are transforming regulatory-grade evidence generation.
These tools streamline dossier preparation, link diverse datasets through knowledge graphs, and ensure reproducibility and traceability for regulators.

Representative Solutions: Aetion, Syneos Health – Data Science Hub, Palantir Foundry for Life Sciences, IQVIA RWE Platform, Aridhia DRE, Cortellis Evidence (Clarivate)

Strategic Impact: Accelerates submission timelines and strengthens confidence in RWD-based evidence.

IV. Manufacturing & Safety: Continuous Quality and Pharmacovigilance

AI is improving how pharma manages safety signals and quality assurance.
Machine learning models detect anomalies in manufacturing data, while NLP systems monitor literature, case reports, and spontaneous databases for adverse events.

Representative Solutions: Genomadix, Medidata Detect (Dassault Systèmes), Drug Safety Triager (by Clarivate), EvidScience, SAS Life Science Analytics Framework, Recursion

Strategic Impact: Enables proactive risk mitigation and regulatory compliance across the production and post-market lifecycle.

V. Market Access & Commercialization: Data-Driven Value Communication

AI is making RWE more actionable for payers and providers.
By integrating claims, clinical, and behavioral data, AI models simulate cost-effectiveness, forecast real-world outcomes, and generate evidence narratives for value dossiers using large language models (LLMs).

Representative Solutions: Komodo Health, Eversana Intelligence, Clarify Health, ZS RWE Navigator, Aktana, Optum Life Sciences

Strategic Impact: Strengthens value demonstration, accelerates reimbursement negotiations, and supports evidence-driven lifecycle management.

VI. Patient Access & Post-Market: Continuous Evidence Beyond Launch

In the post-launch phase, the focus shifts from trial efficacy to real-world impact.

AI-enabled RWE platforms integrate longitudinal data from EHRs, claims, registries, wearables, and digital therapeutics to generate continuous evidence on outcomes, safety, and adherence.
Machine learning models support early detection of safety signals and adherence risks, while causal and temporal analytics provide comparative effectiveness insights across patient segments.
Generative AI tools further streamline post-market safety reporting and regulatory communication.

Representative Solutions: Verily Evidence Generation Platform, OM1, HealthVerity, Huma, Sensyne Health, Triomics

Strategic Impact: AI enables pharma companies to evolve from episodic reporting to continuous, data-driven post-market surveillance—enhancing patient safety, optimizing therapy use, and strengthening payer and regulatory confidence.

The Emerging RWE Operating Model

AI’s role in RWE is shifting from project-level experimentation to enterprise integration.

Pharma companies are increasingly adopting evidence generation platforms that unify RWD access, governance, and analytics. The long-term shift is toward continuous evidence loops — connecting discovery insights, clinical outcomes, and post-market feedback into a single, adaptive ecosystem.

This model aligns with broader industry trends:

• Regulatory openness to hybrid and synthetic evidence designs
• Growth of federated data networks and privacy-preserving analytics
• Integration of generative AI in scientific documentation and medical writing

Strategic Outlook

The next generation of RWE will be defined by interoperability, transparency, and automation. AI will play a foundational role in ensuring evidence is not only generated faster but also validated, explainable, and regulatory-grade.

For pharma, this evolution means shifting RWE from a supporting function to a core enabler of strategic, data-driven decision-making across the product lifecycle.

Industry Collaboration Spotlight: The Next Wave of AI-Driven RWE Innovation

The shift toward AI-enabled Real-World Evidence is opening new pathways for collaboration between pharma, technology providers, and data innovators.

To support this transformation, R2GConnect has launched the Pharma Channel: Real-World Evidence & Advanced Analytics, an initiative designed to connect pharmaceutical companies with startups and scaleups developing next-generation RWE and AI analytics solutions.

This open call invites companies working on evidence generation, patient recruitment, post-market analytics, and HEOR automation to present their solutions directly to pharma decision-makers.

Applications are open until 12 December 2025. Selected participants will gain the opportunity to explore co-development pilots, partnership discussions, and visibility across R2GConnect’s global pharma network.

Learn more and apply via R2GConnect’s Pharma Channel